Lexicon Pharmaceuticals (LXRX) Reports Mixed Q4 Results
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.41 --0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
DOYU, TWIN, FLO, More
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
DOYU, TWIN, FLO, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $343 thousand versus the consensus estimate of $290 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance
- Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
- Webull Corp (BULL) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
